0001104659-20-020293.txt : 20200213 0001104659-20-020293.hdr.sgml : 20200213 20200213170629 ACCESSION NUMBER: 0001104659-20-020293 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20200213 DATE AS OF CHANGE: 20200213 GROUP MEMBERS: CHRISTOPH KRAIKER GROUP MEMBERS: DELIA BLEYER GROUP MEMBERS: JAMES PLEDGER GROUP MEMBERS: MARC KRIEGSMANN GROUP MEMBERS: NEXTECH IV GP S.A R.L. GROUP MEMBERS: NEXTECH IV ONCOLOGY, S.C.S. SICAV-SIF GROUP MEMBERS: NEXTECH V GP S.A R.L. GROUP MEMBERS: THOMAS LIPS SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc. CENTRAL INDEX KEY: 0001676725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474268251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91018 FILM NUMBER: 20611862 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-6209 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Ideaya Biosciences, Inc. DATE OF NAME CHANGE: 20160609 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Nextech V Oncology S.C.S., SICAV-SIF CENTRAL INDEX KEY: 0001712922 IRS NUMBER: 000000000 STATE OF INCORPORATION: N4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 7, RUE LOU HEMMER CITY: LUXEMBOURG-FINDEL STATE: N4 ZIP: L-1748 BUSINESS PHONE: 352-246-160-6000 MAIL ADDRESS: STREET 1: 7, RUE LOU HEMMER CITY: LUXEMBOURG-FINDEL STATE: N4 ZIP: L-1748 SC 13G 1 tm207791d2_sc13g.htm SC 13G

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

(Amendment No. ___)

 

IDEAYA Biosciences, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

45166A 102

(CUSIP Number)

 

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨     Rule 13d-1(b)

 

x     Rule 13d-1(c)

 

¨     Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

  

 

 

CUSIP NO. 45166A 102 13 G Page 2 of 16

 

1 NAMES OF REPORTING PERSONS
Nextech V Oncology, S.C.S., SICAV-SIF
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)   x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
760,404
  6 SHARED VOTING POWER
0
  7

SOLE DISPOSITIVE POWER

760,404

  8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 760,404
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.7% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

  

(1)This Schedule 13G is filed by Nextech V Oncology, S.C.S., SICAV-SIF (“Nextech V LP”), Nextech V GP S.à r.l. (“Nextech V GP”), Nextech IV Oncology, S.C.S. SICAV-SIF (“Nextech IV LP”), Nextech IV GP S.à r.l. (“Nextech IV GP”), Thomas Lips (“Lips”), Dalia Bleyer (“Bleyer”), James Pledger (“Pledger”), Marc Kriegsmann (“Kriegsmann”) and Christoph Kraiker (“Kraiker” and together with Nextech V LP, Nextech V GP, Nextech IV LP, Nextech IV GP, Lips, Bleyer, Pledger, and Kriegsmann, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 3 of 16

 

1 NAMES OF REPORTING PERSONS
Nextech V GP S.à r.l.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
760,404
  6 SHARED VOTING POWER
0
  7

SOLE DISPOSITIVE POWER

760,404

  8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 760,404
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.7% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 4 of 16

 

1 NAMES OF REPORTING PERSONS
Nextech IV Oncology, S.C.S. SICAV-SIF
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
643,419
  6 SHARED VOTING POWER
0
  7

SOLE DISPOSITIVE POWER

643,419

  8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 643,419
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.2% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 5 of 16

 

1 NAMES OF REPORTING PERSONS
Nextech IV GP S.à r.l.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
643,419
  6 SHARED VOTING POWER
0
  7

SOLE DISPOSITIVE POWER

643,419

  8 SHARED DISPOSITIVE POWER
0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 643,419
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.2% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 6 of 16

 

1 NAMES OF REPORTING PERSONS
Thomas Lips
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
0
  6 SHARED VOTING POWER
1,403,823
  7

SOLE DISPOSITIVE POWER

0

  8 SHARED DISPOSITIVE POWER
1,403,823

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,403,823
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.9% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 7 of 16

 

1 NAMES OF REPORTING PERSONS
James Pledger
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United Kingdom

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
0
  6 SHARED VOTING POWER
760,404
  7

SOLE DISPOSITIVE POWER

0

  8 SHARED DISPOSITIVE POWER
760,404

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 760,404
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.7% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

 

CUSIP NO. 45166A 102 13 G   Page 8 of 16

 

1 NAMES OF REPORTING PERSONS
Delia Bleyer
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Lithuania

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
0
  6 SHARED VOTING POWER
760,404
  7

SOLE DISPOSITIVE POWER

0

  8 SHARED DISPOSITIVE POWER
760,404

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 760,404
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.7% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 9 of 16

 

1 NAMES OF REPORTING PERSONS
Marc Kriegsmann
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Germany

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
0
  6 SHARED VOTING POWER
643,419
  7

SOLE DISPOSITIVE POWER

0

  8 SHARED DISPOSITIVE POWER
643,419

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 643,419
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.2% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 10 of 16

 

1 NAMES OF REPORTING PERSONS
Christoph Kraiker
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)		 (a)   ¨    (b)      x (1)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Germany

NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON
WITH		 5 SOLE VOTING POWER
0
  6 SHARED VOTING POWER
643,419
  7

SOLE DISPOSITIVE POWER

0

  8 SHARED DISPOSITIVE POWER
643,419

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 643,419
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.2% (2)
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

 

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 11 of 16

 

Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”) of IDEAYA Biosciences, Inc. (the “Issuer”).

 

Item 1(a)Name of Issuer:

 

IDEAYA Biosciences, Inc.

 

Item 1(b)Address of Issuer’s principal executive offices:

 

7000 Shoreline Court, Suite 350

South San Francisco, California 94080

 

Items 2(a)Name of Reporting Persons filing:

 

  Nextech V Oncology, S.C.S., SICAV-SIF (“Nextech V LP”)
  Nextech V GP S.à r.l. (“Nextech V GP”)
  Nextech IV Oncology, S.C.S. SICAV SIF (“Nextech IV LP”)
  Nextech IV GP S.à r.l. (“Nextech IV GP”).
  Thomas Lips (“Lips”)
  James Pledger (“Pledger”)
  Dalia Bleyer (“Bleyer”)
  Marc Kriegsmann (“Kriegsmann”)
  Christoph Kraiker (“Kraiker”)

 

Item 2(b)Address or principal business office or, if none, residence:

 

The address of the principal business office of Nextech V LP, Nextech V GP and its managing members is:

8 rue Lou Hemmer

L-1748 Senningerberg

Grand-Duchy of Luxembourg

 

The address of the principal business office of Nextech IV LP, Nextech IV GP and its managing members is:

1c, rue Gabriel Lippmann
L-5365 Munsbach
Grand Duchy of Luxembourg

 

Item 2(c)Citizenship:

 

    Name Citizenship or Place of Organization
    Nextech V LP Luxembourg
    Nextech V GP Luxembourg
    Nextech IV LP Luxembourg
    Nextech IV GP Luxembourg
    Lips Switzerland
    Pledger United Kingdom
    Bleyer Lithuania
    Kriegsmann Germany
    Christoph Kraiker Germany

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 12 of 16

 

Item 2(d)Title of class of securities:

Common Stock, $0.0001 par value per share

 

Item 2(e)CUSIP No.:

45166A 102

 

Item 3If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

 

Not applicable.

 

Item 4Ownership

The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2019.

 

Reporting Persons  Shares of
Common
Stock Held
Directly		   Sole
Voting
Power		   Shared
Voting
Power (1)		   Sole
Dispositive
Power		   Shared
Dispositive
Power (1)		   Beneficial
Ownership		   Percentage
of Class
(1)(4)		 
Nextech V LP   760,404    760,404    0    760,404    0    760,404    3.7%
Nextech V GP (2)   0    760,404    0    760,404    0    760,404    3.7%
Nextech IV LP   643,419    643,419    0    643,419    0    643,419    3.2%
Nextech IV GP(3)   0    643,419    0    643,419    0    643,419    3.2%
Lips (2)(3)   0    0    1,403,823    0    1,403,823    1,403,823    6.9%
Pledger (2)   0    0    760,404    0    760,404    760,404    3.7%
Bleyer (2)   0    0    760,404    0    760,404    760,404    3.7%
Kriegsmann (3)   0    0    643,419    0    643,419    643,419    3.2%
Kraiker (3)   0    0    643,419    0    643,419    643,419    3.2%

 

  (1) Consists of (i) 760,404 shares of Common Stock of the Issuer held directly by Nextech V LP; and (ii) 643,419 shares of Common Stock of the Issuer held directly by Nextech IV LP.
  (2) The shares are held by Nextech V LP. Nextech V GP serves as the sole general partner of Nextech V LP and has sole voting and investment control over the shares owned by Nextech V LP and may be deemed to own beneficially the shares held by Nextech V LP. Nextech V GP owns no securities of the Issuer directly. Bleyer, Pledger and Lips are members of the board of managers of Nextech V GP and share voting and dispositive power over the shares held by Nextech V LP, and may be deemed to own beneficially the shares held by Nextech V LP. The managing members own no securities of the Issuer directly.
  (3) The shares are held by Nextech IV LP. Nextech IV GP serves as the sole general partner of Nextech IV LP and has sole voting and investment control over the shares owned by Nextech IV LP and may be deemed to own beneficially the shares held by Nextech IV LP. Nextech IV GP owns no securities of the Issuer directly. Lips, Kriegsmann and Kraiker are members of the board of managers of Nextech IV GP and share voting and dispositive power over the shares held by Nextech IV LP, and may be deemed to own beneficially the shares held by Nextech IV LP. The managing members own no securities of the Issuer directly.
  (4) The (i) 760,404 shares of Common Stock beneficially owned by each of Nextech V LP, Nextech V GP, Pledger and Bleyer represent 3.7% of the Issuer’s outstanding Common Stock; (ii) 643,419 shares of Common Stock beneficially owned by each of Nextech IV LP, Nextech IV GP, Kriegsmann and Kraiker represent 3.2% of the Issuer’s outstanding Common Stock; and (iii) 1,403,823 shares of Common Stock beneficially owned by Lips represents 6.9% of the Issuer’s outstanding Common Stock. These percentages are based on 20,331,095 shares of common stock outstanding as of November 1, 2019, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on November 13, 2019.

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 13 of 16

 

Item 5Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

 

Item 6Ownership of More than Five Percent on Behalf of Another Person

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

 

Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

 

Item 8Identification and Classification of Members of the Group

Not applicable.

 

Item 9Notice of Dissolution of Group

Not applicable.

 

Item 10Certifications

By signing below, the undersigned certifies that to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 14 of 16

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in the attached statement on Schedule 13G is true, complete and correct.

 

Dated: February 13, 2020

 

Nextech V Oncology, S.C.S., SICAV-SIF

 

By: Nextech V GP S.à r.l.
Its: General Partner

 

By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

Nextech V GP S.à r.l.  
     
By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

Nextech IV Oncology, S.C.S., SICAV-SIF

 

By: Nextech IV GP S.à r.l.
Its: General Partner

 

By: /s/ Marc Kriegsmann  
  Marc Kriegsmann, Managing Member  
     
By: /s/ Christoph Kraiker  
  Christoph Kraiker, Managing Member  

 

Nextech IV GP S.à r.l.  
     
By: /s/ Marc Kriegsmann  
  Marc Kriegsmann, Managing Member  
     
By: /s/ Christoph Kraiker  
  Christoph Kraiker, Managing Member  

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 15 of 16

 

/s/ Thomas Lips  
Thomas Lips  
   
/s/ James Pledger  
James Pledger  
   
/s/ Dalia Bleyer  
Dalia Bleyer  
   
/s/ Marc Kriegsmann  
Marc Kriegsmann  
   
/s/ Christoph Kraiker  
Christoph Kraiker  

 

 

 

 

CUSIP NO. 45166A 102 13 G Page 16 of 16

 

Exhibit(s):

 

Exhibit 99.1:          Joint Filing Statement

 

 

 

 

 EX-99.1 2 tm207791d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

  

JOINT FILING STATEMENT

 

We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of IDEAYA Biosciences, Inc. is filed on behalf of each of us.

 

 

Dated: February 13, 2020

 

Nextech V Oncology, S.C.S., SICAV-SIF

 

By: Nextech V GP S.à r.l.
Its: General Partner

 

By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

Nextech V GP S.à r.l.  
     
By: /s/ Dalia Bleyer  
  Dalia Bleyer, Managing Member  
     
By: /s/ James Pledger  
  James Pledger, Managing Member  

 

Nextech IV Oncology, S.C.S. SICAV-SIF

 

By: Nextech IV GP S.à r.l.
Its: General Partner

 

By: /s/ Marc Kriegsmann  
  Marc Kriegsmann, Managing Member  
     
By: /s/ Christoph Kraiker  
  Christoph Kraiker, Managing Member  

 

Nextech IV GP S.à r.l.  
     
By: /s/ Marc Kriegsmann  
  Marc Kriegsmann, Managing Member  
     
By: /s/ Christoph Kraiker  
  Christoph Kraiker, Managing Member  

 

 

 

 

/s/ Thomas Lips  
Thomas Lips  
   
/s/ James Pledger  
James Pledger  
   
/s/ Dalia Bleyer  
Dalia Bleyer  
   
/s/ Marc Kriegsmann  
Marc Kriegsmann  
   
/s/ Christoph Kraiker  
Christoph Kraiker